IBEX 35
10.883,50 +29,10 (+0,27%) Euro Stoxx 50
4.897,76 -23,46 (-0,48%) Dólar/Euro
1,0711 -0,0007 (-0,06%) Petróleo Brent
84,09 +0,65 (+0,78%) Oro
2.315,40 +4,40 (+0,19%) Bitcoin EUR
54.072,04 +977,54 (+1,84%)
LAVA Therapeutics N.V. (LVTX)
LAVA Therapeutics N.V.
Yalelaan 62
Utrecht 3584 CM
Netherlands
31 85 016 3100
https://www.lavatherapeutics.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 37
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Stephen Allen Hurly M.B.A., M.Sc. | CEO, President & Executive Director | N/A | N/A | 1968 |
| Mr. Fred M. Powell CPA | Chief Financial Officer | N/A | N/A | 1961 |
| Dr. Hans van der Vliet M.D., Ph.D. | Chief Scientific Officer | N/A | N/A | 1974 |
| Ms. Amy Garabedian J.D. | General Counsel & Corporate Secretary | N/A | N/A | 1976 |
| Mr. Wouter van Hunnik | VP & Head of Human Resources | N/A | N/A | N/A |
| Dr. Ton Adang Ph.D. | Chief Development Officer | N/A | N/A | 1961 |
| Dr. Charles Q. Morris M.D., MBChB, MRCP (UK), Ph.D. | Chief Medical Officer | N/A | N/A | 1965 |
Descripción
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
Gobierno corporativo
El ISS Governance QualityScore de LAVA Therapeutics N.V., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
